Erica Weinstein
Gründer bei Profound Therapeutics
Aktive Positionen von Erica Weinstein
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01.01.2015 | - |
Profound Therapeutics
 Profound Therapeutics Pharmaceuticals: OtherHealth Technology Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then. | Gründer | 01.01.2020 | - |
Karriereverlauf von Erica Weinstein
Ausbildung von Erica Weinstein
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
| Emory University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Private Equity Investor | 1 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Profound Therapeutics
Profound Therapeutics Pharmaceuticals: OtherHealth Technology Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then. | Health Technology |
- Börse
- Insiders
- Erica Weinstein
- Erfahrung